Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

If you continue to have this issue please contact [email protected]. Mepolizumab reduced the risk for a first severe exacerbation and a first exacerbation requiring ED visit and/or ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

Participants were randomized to mepolizumab at a 100-mg subcutaneous dose every 4 weeks or to matching placebo as add-on maintenance treatment to background therapy. In both trials, mepolizumab ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Nucala (generic name mepolizumab) works alongside inhalers. “COPD isn’t just a disease, it’s a relentless cycle,” said Jean Wright, MD, chief executive officer of the COPD Foundation ...

The FDA has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype and are inadequately ...